60 Degrees Pharmaceuticals Validates Babesia's Link to Chronic Fatigue Theory.
ByAinvest
Monday, Dec 29, 2025 8:07 am ET1min read
SXTP--
60 Degrees Pharmaceuticals announced that Babesia, a parasite causing tick-borne babesiosis, was found in 24% of 50 patients with chronic fatigue in a study published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The study validates the continuation of the B-FREE study to evaluate the efficacy and safety of ARAKODA (tafenoquine) for treating chronic babesiosis.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet